COX-2 as a potential biomarker and therapeutic target in melanoma

Diana Valentina Tudor, Ioana Bâldea, Mihai Lupu, et al.


With a constantly increasing incidence, cutaneous melanoma has raised the need for a better understanding of its complexmicroenvironment that may further guide therapeutic options. Melanoma is a model tumor in immuno-oncology. Inflammationrepresents an important hallmark of cancer capable of inducing and sustaining tumor development. The inflammatory processalso orchestrates the adaptative immunosuppression of tumor cells that helps them to evade immune destruction. Besides its rolein proliferation, angiogenesis, and apoptosis, cyclooxygenase-2 (COX-2) is a well-known promoter of immune suppression inmelanoma. COX-2 inhibitors are closely involved in this condition. This review attempts to answer two controversial questions: isCOX-2 a valuable prognostic factor? Among all COX-2 inhibitors, is celecoxib a suitable adjuvant in melanoma therapy?

Cite this article as: Tudor DV, Bâldea I, Lupu M, KacsoT, Kutasi E, Hopârtean A,et al. COX-2 as a potential biomarker and therapeutic target in melanoma.Cancer Biol Med. 2020; 17: 20-31. doi: 10.20892/j.issn.2095-3941.2019.0339


Melanoma; inflammation, COX-2; COX-2 inhibitors; celecoxib

Full Text: PDF


  • There are currently no refbacks.